Ivonescimab Updated Data to be Featured at ASCO 2023

Summit Therapeutics is Currently Enrolling in a Phase III Study with Additional Phase III Study Planned for Third Quarter 2023 for Ivonescimab

... | June 1, 2023

Related Keywords

Li Zhang ,Zhejiang ,China ,Australia ,United Kingdom ,Yu Zhang ,Weifeng ,Shaanxi ,Menlo Park ,California ,United States ,Ming Zhou ,Anhui ,Japan ,Canada ,Yingying ,Liaoning ,Chicago ,Illinois ,Li Zhuang ,Henan ,Wu Zhuang ,American ,Weidong Zhang ,Bryan Huang ,Jianhua Chen ,Qitao Yu ,Yanqiu Zhao ,Michelle Xia ,Yuanyuan Zhao ,Ningning Zhou ,Wenfeng Fang ,Yunpeng Yang ,Likun Chen ,World Health Organization ,Exchange Commission ,Summit Therapeutics Inc ,Team Summit ,Nasdaq ,Summit Therapeutic Mission Statement ,Drug Administration ,American Cancer Society ,American Society Of Clinical Oncology ,Akeso Inc ,Sun Yat Sen University Cancer Center ,Twitter ,Summit Therapeutics ,Clinical Oncology ,Annual Meeting ,Sunday June ,Central Time ,Lung Cancer ,Non Small Cell Metastatic Poster ,Sun Yat Sen University Cancer ,Nasdaq Global Market ,Private Securities Litigation Reform Act ,Yixin Wan ,Weifeng Song ,Cancer Society ,Lung Cancer Statistics ,Show Common ,Health Organization ,Cancer Epidemiology ,Summit Therapeutics Inc Stock Exchange ,News ,Information ,Press Release ,Summit ,Herapeutics ,Us ,Currently ,Unrolling ,N ,Hase ,Wii ,Study ,Ith ,Dditional ,Planned ,Or ,Third ,Quarter ,023 ,Or Smmt Us86627t1088 ,